Use of clarithromycin and roxithromycin and risk of cardiac death: Cohort study

BMJ (Online)

Volumn 349, Issue , 2014, Pages

  Svanström, Henrik ^a   Pasternak, Björn ^a   Hviid, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; CYTOCHROME P450 3A; MACROLIDE; PENICILLIN V; POTASSIUM; ROXITHROMYCIN;

ADULT; AGED; ARTICLE; ATTRIBUTABLE RISK; CARDIOTOXICITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DENMARK; DRUG METABOLISM; FEMALE; GENETIC PREDISPOSITION; HEART ARRHYTHMIA; HEART DEATH; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; POTASSIUM CURRENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; REPOLARIZATION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SCORING SYSTEM; TORSADE DES POINTES; TREATMENT OUTCOME;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARDIOVASCULAR DISEASES; CLARITHROMYCIN; COHORT STUDIES; CYTOCHROME P-450 CYP3A; DENMARK; ENZYME INHIBITORS; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; PENICILLIN V; PROPENSITY SCORE; REGISTRIES; ROXITHROMYCIN; SEX FACTORS;

EID: 84907371523     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.g4930     Document Type: Article

References (31)

1. Justo D, Zeltser D. Torsades de pointes induced by antibiotics. Eur J Intern Med 2006;17:254-9. (Pubitemid 43817517)
2. Mosholder AD, Mathew J, Alexander JJ, Smith H, Nambiar S. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 2013;368:1665-8.
3. Owens RC Jr, Nolin TD. Antimicrobial-associated QT interval prolongation: pointes of interest. Clin Infect Dis 2006;43:1603-11. (Pubitemid 44910994)
4. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-72. (Pubitemid 37311108)
5. Hensey C, Keane D. Clarithromycin induced torsade de pointes. Ir J Med Sci 2008;177:67-8.
6. Huang BH, Wu CH, Hsia CP, Yin CC. Azithromycin-induced torsade de pointes. Pacing Clin Electrophysiol 2007;30:1579-82.
7. Kamochi H, Nii T, Eguchi K, Mori T, Yamamoto A, Shimoda K, et al. Clarithromycin associated with torsades de pointes. Jpn Circ J 1999;63:421-2. (Pubitemid 29252254)
8. Katapadi K, Kostandy G, Katapadi M, Hussain KM, Schifter D. A review of erythromycin-induced malignant tachyarrhythmia-torsade de pointes: a case report. Angiology 1997;48:821-6. (Pubitemid 27418040)
9. Kezerashvili A, Khattak H, Barsky A, Nazari R, Fisher JD. Azithromycin as a cause of QT-interval prolongation and torsade de pointes in the absence of other known precipitating factors. J Interv Card Electrophysiol 2007;18:243-6. (Pubitemid 46944944)
10. Koh TW. Risk of torsades de pointes from oral erythromycin with concomitant carbimazole (methimazole) administration. Pacing Clin Electrophysiol 2001;24:1575-6. (Pubitemid 32977321)
11. Piquette RK. Torsade de pointes induced by cisapride/clarithromycin interaction. Ann Pharmacother 1999;33:22-6. (Pubitemid 29056553)
12. Promphan W, Khongphatthanayothin A, Horchaiprasit K, Benjacholamas V. Roxithromycin induced torsade de pointes in a patient with complex congenital atrioventricular block. Pacing Clin Electrophysiol 2003;26:1424-6. (Pubitemid 36683740)
13. Shaffer D, Singer S, Korvick J, Honig P. Concomitant risk factors in reports of torsades de pointes associated with macrolide use: review of the United States Food and Drug Administration Adverse Event Reporting System. Clin Infect Dis 2002;35:197-200. (Pubitemid 34753906)
14. Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004;351:1089-96.
15. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
16. Svanstrom H, Pasternak B, Hviid A. Use of azithromycin and death from cardiovascular causes. N Engl J Med 2013;368:1704-12.
17. Straus SM, Sturkenboom MC, Bleumink GS, Dieleman JP, van der Lei J, de Graeff PA, et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 2005;26:2007-12. (Pubitemid 41435722)
18. Rubinstein E. Comparative safety of the different macrolides. Int J Antimicrob Agents 2001;18:S71-6. (Pubitemid 33713507)
19. Yamazaki H, Shimada T. Comparative studies of in vitro inhibition of cytochrome P450 3A4-dependent testosterone 6beta-hydroxylation by roxithromycin and its metabolites, troleandomycin, and erythromycin. Drug Metab Dispos 1998;26:1053-7. (Pubitemid 28516578)
20. Pedersen CB. The Danish civil registration system. Scand J Public Health 2011;39(7 suppl):22-5.
21. Kildemoes HW, Sorensen HT, Hallas J. The Danish national prescription registry. Scand J Public Health 2011;39(7 suppl):38-41.
22. Helweg-Larsen K. The Danish register of causes of death. Scand J Public Health 2011;39(7 suppl):26-9.
23. Lynge E, Sandegaard JL, Rebolj M. The Danish national patient register. Scand J Public Health 2011;39(7 suppl):30-3.
24. Brookhart MA, Wyss R, Layton JB, Sturmer T. Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 2013;6:604-11.
25. Sturmer T, Schneeweiss S, Brookhart MA, Rothman KJ, Avorn J, Glynn RJ. Analytic strategies to adjust confounding using exposure propensity scores and disease risk scores: nonsteroidal antiinflammatory drugs and short-term mortality in the elderly. Am J Epidemiol 2005;161:891-8. (Pubitemid 40577844)
26. Indiana University School of Medicine. P450 drug interaction table: Abbreviated "clinically relevant" table. 2013. http://medicine.iupui. edu/clinpharm/ddis/clinical-table/.
27. Kannankeril P, Roden DM, Darbar D. Drug-induced long QT syndrome. Pharmacol Rev 2010;62:760-81.
28. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22. (Pubitemid 38269278)
29. Owens RC Jr. QT prolongation with antimicrobial agents: understanding the significance. Drugs 2004;64:1091-124. (Pubitemid 38744523)
30. Ohtani H, Taninaka C, Hanada E, Otaki H, Sato H, Sawada Y, et al. Comparative pharmacodynamic analysis of Q-T interval prolongation induced by the macrolides clarithromycin, roxithromycin, and azithromycin in rats. Antimicrob Agents Chemother 2000;44:2630-7.
31. Volberg WA, Koci BJ, Su W, Lin J, Zhou J. Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J Pharmacol Exp Ther 2002;302:320-7. (Pubitemid 34680454)